NO902633D0 - Fremgangsmaate for fremstilling av terapeutisk aktive imidazolyl-alkensyrer. - Google Patents

Fremgangsmaate for fremstilling av terapeutisk aktive imidazolyl-alkensyrer.

Info

Publication number
NO902633D0
NO902633D0 NO902633A NO902633A NO902633D0 NO 902633 D0 NO902633 D0 NO 902633D0 NO 902633 A NO902633 A NO 902633A NO 902633 A NO902633 A NO 902633A NO 902633 D0 NO902633 D0 NO 902633D0
Authority
NO
Norway
Prior art keywords
alcohic
acids
procedure
preparation
therapeutic active
Prior art date
Application number
NO902633A
Other languages
English (en)
Other versions
NO902633L (no
Inventor
Joseph Alan Finkelstein
Joseph Weinstock
Richard Mcculloch Keenan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO902633D0 publication Critical patent/NO902633D0/no
Publication of NO902633L publication Critical patent/NO902633L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO90902633A 1989-06-14 1990-06-13 Fremgangsmaate for fremstilling av terapeutisk aktive imidazolyl-alkensyrer. NO902633L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36605589A 1989-06-14 1989-06-14
US50595890A 1990-04-06 1990-04-06

Publications (2)

Publication Number Publication Date
NO902633D0 true NO902633D0 (no) 1990-06-13
NO902633L NO902633L (no) 1990-12-17

Family

ID=27003207

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90902633A NO902633L (no) 1989-06-14 1990-06-13 Fremgangsmaate for fremstilling av terapeutisk aktive imidazolyl-alkensyrer.

Country Status (16)

Country Link
EP (1) EP0403158A3 (no)
JP (1) JP2958055B2 (no)
KR (1) KR910000659A (no)
CN (2) CN1048039A (no)
AU (1) AU634551B2 (no)
CA (1) CA2018443A1 (no)
FI (1) FI902969A0 (no)
HU (1) HU209296B (no)
IE (1) IE902139A1 (no)
IL (1) IL94699A0 (no)
MA (1) MA22481A1 (no)
NO (1) NO902633L (no)
NZ (1) NZ233996A (no)
PH (1) PH26976A (no)
PL (5) PL290123A1 (no)
PT (1) PT94374A (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5112819A (en) * 1989-10-10 1992-05-12 Glaxo Group Limited Imidazole derivatives, pharmaceutical compositions and use
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
US5449682A (en) * 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
NZ238688A (en) * 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
GB9027197D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027201D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027209D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027198D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6028091A (en) * 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027212D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
US5187179A (en) * 1991-03-22 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5252574A (en) * 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5175164A (en) * 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4132633A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Cyclisch substituierte imidazolyl-propensaeurederivate
DE4132631A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Imidazolyl-propensaeurederivate
GB9121463D0 (en) * 1991-10-10 1991-11-27 Smithkline Beecham Corp Medicament
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5389661A (en) * 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5240953A (en) * 1992-01-30 1993-08-31 Ortho Pharmaceutical Corporation Substituted triazoles as angiotensin ii inhibitors
DE4206042A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl-substituierte imidazopyridine
DE4206045A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl substituierte pyridone
DE4206041A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl-substituierte imidazolylpropensaeurederivate
DE4206043A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl-substituierte imidazole
DE4210787A1 (de) * 1992-04-01 1993-10-07 Bayer Ag Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate
FR2689508B1 (fr) * 1992-04-01 1994-06-17 Fournier Ind & Sante Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
DE4212796A1 (de) * 1992-04-16 1993-10-21 Bayer Ag Propenoyl-imidazolderivate
DE4215588A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Biphenylmethyl-substituierte Pyridone
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
EP0650484B1 (en) * 1992-07-17 2000-01-26 Smithkline Beecham Corporation Endothelin receptor antagonists
US5559105A (en) * 1992-07-17 1996-09-24 Smithkline Beecham Corporation Endothelin receptor antagonists
DE4319041A1 (de) * 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
US5629345A (en) * 1993-07-23 1997-05-13 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5965620A (en) * 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US20030004202A1 (en) 1997-04-28 2003-01-02 Smithkline Beecham Corporation Endothelin receptor antagonists
JPH10505085A (ja) * 1994-09-02 1998-05-19 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗薬
DE69626986T2 (de) * 1995-08-02 2004-02-05 Smithkline Beecham Corp. Endothelinrezeptorantagonist
AP9801182A0 (en) * 1995-08-02 1998-01-31 Smithkline Beecham Corp Endothelin receptor antagonists.
EP0868180A4 (en) * 1995-12-21 1999-08-04 Smithkline Beecham Corp ENDOTHELINM RECEPTOR ANTOGONISTS
US6022886A (en) * 1996-02-01 2000-02-08 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1997028159A1 (en) * 1996-02-01 1997-08-07 Smithkline Beecham Corporation Endothelin receptor antagonists
EP0885217A4 (en) * 1996-02-01 1999-04-21 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
ID25640A (id) 1998-03-04 2000-10-19 Takeda Chemical Industries Ltd Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
EP1444988A4 (en) 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4835154A (en) * 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US4798843A (en) * 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles

Also Published As

Publication number Publication date
HU209296B (en) 1994-04-28
EP0403158A3 (en) 1991-12-18
PL285590A1 (en) 1991-09-23
EP0403158A2 (en) 1990-12-19
IL94699A0 (en) 1991-04-15
PL290125A1 (en) 1992-06-01
IE902139L (en) 1990-12-14
AU5690390A (en) 1990-12-20
MA22481A1 (fr) 1992-12-31
CN1048039A (zh) 1990-12-26
IE902139A1 (en) 1991-01-02
JP2958055B2 (ja) 1999-10-06
PH26976A (en) 1992-12-28
PL290123A1 (en) 1992-06-01
PT94374A (pt) 1991-02-08
CA2018443A1 (en) 1990-12-14
HU903846D0 (en) 1990-11-28
CN1079648A (zh) 1993-12-22
HUT54999A (en) 1991-04-29
PL290122A1 (en) 1992-06-01
JPH03115268A (ja) 1991-05-16
NO902633L (no) 1990-12-17
KR910000659A (ko) 1991-01-29
FI902969A0 (fi) 1990-06-13
AU634551B2 (en) 1993-02-25
PL290124A1 (en) 1992-06-01
NZ233996A (en) 1991-04-26

Similar Documents

Publication Publication Date Title
NO902633D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolyl-alkensyrer.
NO904694D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO884154D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive preparater.
NO883974D0 (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO894630D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinuklidin-derivater.
NO884473L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazoler.
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
NO900032D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiazol-forbindelser.
NO883750L (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.
NO883122D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO883485L (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinyl-isokinolinforbindelser.
NO890155L (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolpiperidin-forbindelser.
NO893909D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
NO880667L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylpiperazinyl-alkylen-fenyl-heterocykliske forbindelser.
NO891723L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO882281D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO892871D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO883959L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenolestere.
NO882282L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO890724D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetraazaacenaftylen-derivater.
NO904470D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater.
NO890519D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive propanon-derivater.